Evidence map›Paper›PMID 36225270›Full record

ArticleEuropean heart journal supplements : journal of the European Society of Cardiology2022

May Measurement Month 2017-2019: an analysis of blood pressure screening results from Lithuania

Marius Miglinas, Violeta Ševčenko, Aistė Račaitė, Urtė Žakauskienė, Alvita Vickienė, Vilma Miglinė, Wei Wang, Thomas Beaney, Neil R Poulter, Ernesta Macioniene

Abstract read
In one paragraph

Article in European heart journal supplements : journal of the European Society of Cardiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Marius MiglinasInstitute of Clinical Medicine, Faculty of Medicine, Vilnius University, Universiteto g. 3, Vilnius LT-01513, Lithuania.
Violeta ŠevčenkoInstitute of Clinical Medicine, Faculty of Medicine, Vilnius University, Universiteto g. 3, Vilnius LT-01513, Lithuania.
Aistė RačaitėInstitute of Clinical Medicine, Faculty of Medicine, Vilnius University, Universiteto g. 3, Vilnius LT-01513, Lithuania.
Urtė ŽakauskienėInstitute of Clinical Medicine, Faculty of Medicine, Vilnius University, Universiteto g. 3, Vilnius LT-01513, Lithuania.
Alvita VickienėInstitute of Clinical Medicine, Faculty of Medicine, Vilnius University, Universiteto g. 3, Vilnius LT-01513, Lithuania.
Vilma MiglinėCommunity Well-Being Center, Mykolas Romeris University, Ateities g. 20, Vilnius LT-08303, Lithuania.
Wei WangImperial Clinical Trials Unit, Imperial College London, Stadium House, 68 Wood Lane, London W12 7RH, UK.
Thomas BeaneyImperial Clinical Trials Unit, Imperial College London, Stadium House, 68 Wood Lane, London W12 7RH, UK.
Neil R PoulterImperial Clinical Trials Unit, Imperial College London, Stadium House, 68 Wood Lane, London W12 7RH, UK.
Ernesta MacionieneInstitute of Clinical Medicine, Faculty of Medicine, Vilnius University, Universiteto g. 3, Vilnius LT-01513, Lithuania.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In 2017, Lithuania joined the global May Measurement Month (MMM) campaign which aims at raising awareness of raised blood pressure worldwide. Presented here are the data arising from the 2017, 2018, and 2019 campaigns. An opportunistic cross-sectional survey of individuals aged ≥18 years was carried out in Lithuania in 2017, 2018, and 2019. Two thousand nine hundred and nineteen participants were recruited in the MMM campaigns in response to the media engagement and interactions with the study team. The mean age of participants was 46.1 years (SD 16.3) years, 58.9% were females. Blood pressures were measured using electronic devices provided by Omron according to the MMM protocol. Of the 2919 screened participants, 1308 (44.8%) had hypertension. Of all hypertensive participants, the awareness rate, the treatment rate, and the control rates (<140/90 mmHg) were 79.5%, 41.0%, and 14.2%, respectively. Of those on antihypertensive medication, the control rate was 34.8%. The high percentage of participants with hypertension was either untreated (59.0%) or treated but uncontrolled (65.2%) suggests the usefulness of such screening programmes to improve awareness of hypertension control in Lithuania.

Indexed as

ControlHypertensionMay Measurement MonthPharmaciesScreeningTreatment

Identifiers

PMID36225270
PMCPMC9547500

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.